Venture Visionary Partners LLC lifted its position in Stryker Co. (NYSE:SYK) by 41.4% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 4,296 shares of the medical technology company’s stock after acquiring an additional 1,258 shares during the period. Venture Visionary Partners LLC’s holdings in Stryker were worth $1,046,000 at the end of the most recent quarter.
Several other large investors have also recently made changes to their positions in the stock. Price T Rowe Associates Inc. MD raised its position in shares of Stryker by 1.2% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 29,889,733 shares of the medical technology company’s stock valued at $7,318,132,000 after acquiring an additional 364,668 shares during the period. Bank of New York Mellon Corp raised its holdings in shares of Stryker by 1.8% in the fourth quarter. Bank of New York Mellon Corp now owns 7,331,191 shares of the medical technology company’s stock valued at $1,796,434,000 after purchasing an additional 129,597 shares during the last quarter. Fundsmith LLP raised its holdings in shares of Stryker by 5.7% in the fourth quarter. Fundsmith LLP now owns 6,634,893 shares of the medical technology company’s stock valued at $1,625,814,000 after purchasing an additional 357,755 shares during the last quarter. FMR LLC grew its stake in shares of Stryker by 246.1% in the fourth quarter. FMR LLC now owns 4,189,778 shares of the medical technology company’s stock valued at $1,026,663,000 after buying an additional 2,979,131 shares in the last quarter. Finally, Norges Bank bought a new position in Stryker during the fourth quarter worth $811,698,000. Institutional investors and hedge funds own 71.46% of the company’s stock.
SYK has been the subject of a number of research analyst reports. Cowen lifted their price objective on shares of Stryker from $255.00 to $279.00 and gave the stock an “outperform” rating in a research report on Wednesday, April 28th. Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell lifted their target price on Stryker from $264.00 to $303.00 in a report on Wednesday, April 28th. Oppenheimer lifted their target price on Stryker from $240.00 to $273.00 in a report on Wednesday, April 28th. Guggenheim assumed coverage on Stryker in a report on Monday, January 4th. They set a “neutral” rating for the company. Finally, Truist lifted their target price on Stryker from $245.00 to $255.00 in a report on Wednesday, April 28th. One analyst has rated the stock with a sell rating, six have issued a hold rating and thirteen have given a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average price target of $261.59.
Stryker (NYSE:SYK) last issued its earnings results on Monday, April 26th. The medical technology company reported $1.93 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $1.99 by ($0.06). The business had revenue of $3.95 billion for the quarter, compared to analyst estimates of $3.94 billion. Stryker had a return on equity of 20.94% and a net margin of 12.35%. The firm’s revenue was up 10.2% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.84 EPS. On average, sell-side analysts predict that Stryker Co. will post 7.18 earnings per share for the current year.
In other Stryker news, VP M Kathryn Fink sold 4,000 shares of the business’s stock in a transaction dated Thursday, April 8th. The stock was sold at an average price of $250.00, for a total transaction of $1,000,000.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Glenn S. Boehnlein sold 2,000 shares of the business’s stock in a transaction dated Monday, March 1st. The stock was sold at an average price of $246.01, for a total value of $492,020.00. Following the transaction, the chief financial officer now directly owns 12,321 shares of the company’s stock, valued at approximately $3,031,089.21. The disclosure for this sale can be found here. 6.80% of the stock is currently owned by insiders.
Stryker Corp. engages in the provision of medical technology products and services. It operates through the following segments: Orthopaedics, MedSurg and Neurotechnology and Spine. The Orthopaedics segment provides reconstructive and trauma implant systems. The MedSurg segment deals with surgical equipment and navigation systems, endoscopy, patient handling and reprocessed medical devices.
Featured Story: Limitations of the P/E Growth ratio
Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Co. (NYSE:SYK).
Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.